Daniel G. Stover, MD
Daniel Stover, MD, is a medical oncologist who specializes in the treatment of breast cancer at The Ohio State Comprehensive Cancer Center and assistant professor in the department of internal medicine at The Ohio State University. He attended medical school and completed his residency at the Vanderbilt University School of Medicine in Nashville, TN, and completed his medical oncology and research fellowships at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts.
Articles
HER2CLIMB-02: Tucatinib and T-DM1 for Previously Treated HER2+ Metastatic Breast Cancer
January 11th 2024Daniel Stover, MD, and the Oncology Brothers review results from HER2CLIMB-02, a randomized, double-blind phase 3 trial of tucatinib and T-DM1 in patients with previously treated HER2+ metastatic breast cancer.
Update from KATHERINE on Adjuvant T-DM1 for Residual Invasive HER2+ Early Breast Cancer
January 11th 2024Medical oncologists discuss the recent update from the KATHERINE trial investigating adjuvant T-DM1 (trastuzumab emtansine) following neoadjuvant chemotherapy in patients with residual invasive HER2+ early breast cancer.
Sub-Analysis from APHINITY on Adjuvant Pertuzumab and Trastuzumab in HER2+ Breast Cancer
January 11th 2024Following SABCS 2023, Daniel Stover, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the benefit of adjuvant pertuzumab and trastuzumab according to ER and HER2 expression in patients with HER2+ breast cancer.
